AXA China Region Insurance Company (Bermuda) Limited ("AXA") formally signed an official cooperation agreement with Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration ("Lecheng Administration"). The partnership aims jointly explore more innovative medical insurance models and leverage the top-tier medical resources of Hainan Boao Lecheng to provide customers with more high-quality cross-border medical options. The Hainan Boao Lecheng International Medical Tourism Pilot Zone ("the Pilot Zone") was approved by the State Council[1] in 2013 as the only medical special zone in China, enjoying preferential policies covering licensed medical services, operations, research, and international exchanges. Since approval, the Pilot Zone has attracted leading medical institutions and specialist teams, introducing advanced international treatment protocols, innovative pharmaceuticals, and medical devices into China for trial use – including therapies for rare diseases and cutting-edge cancer treatments. Meanwhile, AXA has partnered with China Biotech Services Holdings Limited to explore Boron Neutron Capture Therapy ("BNCT"), a pioneering initiative now being established within the Pilot Zone. Janet Lee, Chief Life and Health Insurance Officer, AXA Hong Kong and Macau, said, "We are honoured to have signed a cooperation agreement with the Lecheng Administration. As a pioneer in China's medical opening-up, Hainan Boao Lecheng benefits from unique policy advantages and strong support from global healthcare resources. This collaboration will enable AXA to explore innovative healthcare solutions and integrate them into our insurance offerings, providing customers with broader access to advanced treatment options. We look forward to deepening our partnership with Lecheng and other stakeholders to develop innovative medical models, enabling more customers to benefit from Lecheng's licensed medicines, medical devices, and cutting-edge technologies."